Biotechnology company Inovio Pharmaceuticals Inc (NASDAQ:INO) stated on Tuesday its net loss of USD97.0m (USD1.05 per basic and diluted share) for the year ended 31 December 2018.
This marks a decline in earnings when compared with a lower net loss of USD88.2m (USD1.08 per basic and USD1.09 per diluted share) in 2017.
Total revenue of USD30.5m was generated for the year ended 31 December 2018, down over total revenue of USD42.2m in 2017.
The company said the year over year decrease in comparable revenue and grant agreement recognition was primarily due to lower revenues recognised under its collaborative research and development agreement with AstraZeneca, a decrease in grant funding recognised from its DARPA Ebola grant as well as no revenue recognised in 2018 from Roche due to the termination of the agreement in 2017.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial